OncoLink Cancer Treatment and Resources
OncoLink Cancer Treatment and Resources
OncoLink Cancer News - HealthDay

Diagnostic Radiation Ups Breast Cancer Risk in BRCA Carriers

Friday, September 7, 2012 (Last Updated: 09/10/2012)

FRIDAY, Sept. 7 (HealthDay News) -- For BRCA1/2 mutation carriers, exposure to diagnostic radiation before age 30 correlates with a significantly increased risk of breast cancer, with a dose-response pattern, according to a study published online Sept. 6 in BMJ.

Anouk Pijpe, Ph.D., from the Netherlands Cancer Institute in Amsterdam, and colleagues conducted a retrospective cohort study to estimate the risk of breast cancer associated with diagnostic radiation in 1,993 female BRCA1/2 mutation carriers, recruited from 2006 to 2009.

The researchers found that there was a significantly increased risk of breast cancer with any exposure to diagnostic radiation before age 30 (hazard ratio, 1.90), with evidence of a dose-response pattern. The risks by quarter of estimated cumulative dose increased from 1.63 for <0.0020 Gy (95 percent confidence interval [CI], 0.96 to 2.77) to 3.84 for ≥0.0174 Gy (95 percent CI, 1.67 to 8.79). Compared with no exposure, there was an increasing risk with increasing number of radiographs before age 20 and before age 30, based on analysis of the different types of diagnostic procedures. An increased risk of breast cancer was seen for those with a history of mammography before age 30 (hazard ratio, 1.43; 95 percent CI, 0.85 to 2.40). This finding was not due to confounding by indication of family history.

"In this large European study among BRCA1/2 mutation carriers, exposure to diagnostic radiation before age 30 was associated with an increased risk of breast cancer, at dose levels considerably lower than those at which increases have been found in other cohorts exposed to radiation," the authors write. "The results of this study support the recommendation to use non-ionizing radiation imaging techniques (such as magnetic resonance imaging) as the main tool for surveillance in young BRCA1/2 mutation carriers."

One author disclosed financial ties to the life sciences industry; one author receives royalties from BRCA1 testing.

Full Text

Specialties Pediatrics
Family Practice
Psychiatry
Pulmonology
Otolaryngology
Nursing

Copyright © 2012 HealthDay. All rights reserved.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS